JSKN003

JSKN003 is an investigational agent whose form is not stated in the registry developed by Jiangsu Alphamab Biopharmaceuticals and Shanghai JMT-Bio. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: JSKN003 should be administered intravenously on the first day of each 3-week cycle. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT06079983 (JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects) and NCT06846437 (JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer), in HR-positive / HER2-negative breast cancer and HER2-positive breast cancer. The largest, NCT05744427, plans to enrol 725 participants with primary completion expected 2026-07-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.